Immunologic Effects of Combined Protease Inhibitor and Reverse Transcriptase Inhibitor Therapy in Previously Treated Chronic HIV-1 Infection
Overview
Affiliations
Objective: To evaluate the efficacy of combination protease and reverse transcriptase inhibitor therapy in correcting HIV-1-induced lymphocyte subset abnormalities in previously treated adults.
Design: A 48-week observational study of lymphocyte subsets in 12 participants in the Multicenter AIDS Cohort Study who were already taking at least one reverse transcriptase inhibitor and added a protease inhibitor to their treatment regimen. Comparison groups were HIV-seronegative homosexual men, HIV-seronegative heterosexual men, and homosexual HIV-1-infected men who were long-term non-progressors.
Methods: Three-color immunofluorescence and monoclonal antibodies were used to assess HIV-1-induced lymphocyte subset alterations related to immune deficiency and immune activation. Plasma HIV-1 RNA levels were monitored to assess suppression of viral replication.
Results: CD4+ cell counts significantly increased and lymphocyte activation measured as CD38 and HLA-DR expression on CD8+ T cells significantly decreased by 48 weeks. CD4+ cell values remained abnormal even in those who were fully suppressed. Some T-cell activation markers decreased to levels observed in long-term non-progressors. The increase in CD4+ T-cell numbers reached a plateau by week 24, but the increase in resting HLA-DR- CD38-T cells was sustained through week 48. Proportions of CD45RA+ CD62L-selectin+ and CD28+ CD4+ T-cell subsets and Fas expression were not abnormal at baseline compared with seronegative homosexual controls.
Conclusions: The most significant impact of suppression of viral replication was reversal of T-cell activation. However, normalization of lymphocyte subset perturbations associated with chronic HIV-1 infection was not achieved after 1 year of treatment with current combination antiretroviral regimens. More profound viral suppression, therapy for longer than 1 year, or immunologic augmentation may be needed to fully reverse the abnormalities.
Mdletshe N, Thobakgale C, Malaba T, Madlala H, Myer L, Muema D Clin Infect Dis. 2021; 73(12):2205-2216.
PMID: 33606024 PMC: 8677566. DOI: 10.1093/cid/ciab151.
Killian M, Teque F, Sudhagoni R Immunogenetics. 2017; 70(2):99-113.
PMID: 28735348 DOI: 10.1007/s00251-017-1021-7.
Sauter R, Huang R, Ledergerber B, Battegay M, Bernasconi E, Cavassini M Medicine (Baltimore). 2016; 95(42):e5094.
PMID: 27759638 PMC: 5079322. DOI: 10.1097/MD.0000000000005094.
Supranormal thymic output up to 2 decades after HIV-1 infection.
Aguilera-Sandoval C, Yang O, Jojic N, Lovato P, Chen D, Boechat M AIDS. 2016; 30(5):701-11.
PMID: 26730570 PMC: 4767664. DOI: 10.1097/QAD.0000000000001010.
Distinct cytokine patterns in semen influence local HIV shedding and HIV target cell activation.
Olivier A, Masson L, Ronacher K, Walzl G, Coetzee D, Lewis D J Infect Dis. 2013; 209(8):1174-84.
PMID: 24273175 PMC: 3969547. DOI: 10.1093/infdis/jit649.